Melanoma – Friday Pop Quiz 6/26
This 32-year-old man has two sisters each with melanoma, and his father died from metastatic pancreatic cancer. You suspect a germline mutation in which of the following genes?
A. BAP1
B. TERT
C. MITF
D. CDKN2A
E. PTCH
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner Derm In-Review. A product of SanovaWorks.
…
This 32-year-old man has two sisters each with melanoma, and his father died from metastatic pancreatic cancer. You suspect a germline mutation in which of the following genes?
A. BAP1
B. TERT
C. MITF
D. CDKN2A
E. PTCH
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner Derm In-Review. A product of SanovaWorks.
… 
Melanoma remains the most common cause of death among skin cancers. Over the past decade, major leaps have been made in treating advanced melanoma, resulting in unprecedented improvement in survival. Nevertheless, a large room for improvement is still ahead. In his presentation Therapeutic Updates in Melanoma: IO for Earlier Stage Disease presented at the 2020 ODAC Dermatology, Aesthetic and Sur … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference interviewed Dr. Adam Friedman, Professor, Interim Chair of Dermatology, and Residency Program Director at George Washington University, on some of the common misconceptions and controversies surrounding photoprotection.
With ample evidence today that shows that sunscreen both reduces the incidence of me … 
Have you ever come across a patient with a skin cancer that you are not 100% sure should be treated with Mohs surgery or an alternative modality? Or a patient who comes back for a follow-up after skin cancer surgery with an undesirable scar and you wonder if you should have opted for a less invasive option? I certainly have. Some of these nagging questions were answered by a thoughtful, case-based … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. David Miller, Instructor in Dermatology and Medicine at Harvard Medical School and member of the Department of Dermatology and the Department of Medicine at Massachusetts General Hospital, where he is co-director of the Merkel cell carcinoma treatment program. Watch as he shares important … 